Profound Medical Secures Significant Funding
Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) has recently revealed an underwritten public offering aimed at generating substantial funding for its innovative medical technologies. The offering consists of 4,666,700 common shares priced at US$7.50 each, targeting gross proceeds of around US$35 million. This financing initiative marks a pivotal step for the company as it continues to push boundaries in the medical device field.
Utilization of Funds for Technological Advancement
The proceeds from this offering are strategically allocated for several key areas. The company plans to direct a portion of the funds towards the ongoing commercialization of its flagship product, the TULSA-PRO® system, across the United States. The TULSA-PRO® technology combines advanced MRI imaging, robotically driven transurethral ultrasound, and a closed-loop temperature feedback system to enhance treatment precision.
Global Expansion and Development Initiatives
Additionally, Profound Medical is committed to further developing the TULSA-PRO® and the Sonalleve® systems on a global scale. The Sonalleve® system is CE marked and provides innovative treatment options for uterine fibroids and palliative care for patients with bone metastases. With this additional capital, Profound aims to enhance these therapeutic offerings and expand its market reach effectively.
Role of Underwriters and Closing Procedures
Raymond James Ltd. and Lake Street Capital Markets have stepped in as co-lead underwriters for the latest offering, with Titan Partners Group also supporting various aspects of the offering process. The anticipated closing date for the offering is set around December 10, 2024, pending customary conditions and necessary approvals. This supports the company’s confidence in its growth trajectory and operational readiness.
Prospectus and Regulatory Compliance
To ensure transparency and compliance, Profound Medical is filing a final prospectus supplement corresponding with its base shelf prospectus from earlier this year. The prospectus, filed with the appropriate regulatory bodies, outlines the details of the offering and the associated risks involved. Prospective investors are highly encouraged to examine this document for a clearer understanding of the offering’s breadth and implications.
About Profound Medical Corp.
Profound Medical Corp. operates at the forefront of health technology, focusing on the development of incision-free therapies that target diseased tissue effectively. With a commitment to meaningful healthcare solutions, Profound strives to improve patient outcomes through its revolutionary technologies.
Innovative Technologies Leading the Market
The company's TULSA-PRO® system exemplifies this innovative spirit, utilizing cutting-edge technology to provide safe and effective treatment options. As it continues to evolve, Profound’s commitment to improving medical practices ensures its position as a leader in medical device innovations designed to address critical health concerns.
Frequently Asked Questions
What is the purpose of the offering by Profound Medical?
The offering aims to raise funds for the ongoing commercialization and global development of its TULSA-PRO® and Sonalleve® systems.
How many common shares are being offered?
The public offering includes 4,666,700 common shares priced at US$7.50 each.
Who are the underwriters for this offering?
Raymond James Ltd. and Lake Street Capital Markets are the co-lead underwriters for this public offering.
When is the expected closing date for the offering?
The offering is expected to close on or about December 10, 2024, pending customary closing conditions.
What markets are involved in this offering?
The offering will take place in all provinces of Canada, excluding Quebec, and in the United States.
